SCHEMBL10163632

SCHEMBL10163632

COC(=O)c1cc(C(=O)O)n2cccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 7/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
ABL1 P00519 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
MET P08581 1/20 0.48
PDGFRA P16234 1/20 0.48
PRKACA P17612 1/20 0.48
LTK P29376 1/20 0.48
GRK5 P34947 1/20 0.48
KDR P35968 1/20 0.48
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
CSNK1A1 P48729 1/20 0.48
CDK8 P49336 1/20 0.48
CLK2 P49760 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8247383 0.89 KDM4E (0.48) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL4257194 0.82 ALDH1A1 (0.50) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL13162051 0.82 ALDH1A1 (0.42) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL8253920 0.81 KDM4E (0.40) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL29919476 0.80 KDM4E (0.54) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL823315 0.78 ALDH1A1 (0.56) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL4255419 0.78 ALDH1A1 (0.46) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL4215549 0.77 PIM1 (0.45) KDM4EALDH1A1JAK2RETPRKACA
SCHEMBL10163631 0.77 ALDH1A1 (0.50) KDM4EALDH1A1DAPK3JAK2PRKD3
SCHEMBL10165302 0.74 ALDH1A1 (0.58) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ADAMTS4, ADAMTS1, ADAMTS5 KDM4E 418/4885ALDH1A1 3954/4885DAPK3 1596/4885
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 KDM4E 2058/4885ALDH1A1 1806/4885DAPK3 960/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 KDM4E 2058/4885ALDH1A1 1806/4885DAPK3 960/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 KDM4E 2058/4885ALDH1A1 1806/4885DAPK3 960/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 KDM4E 2058/4885ALDH1A1 1806/4885DAPK3 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.